Impact of Pseudomonas aeruginosa carriage on intensive care unit-acquired pneumonia: a European multicentre prospective cohort study.

In vitro potentiation of tetracyclines in Pseudomonas aeruginosa by RW01, a new cyclic peptide.

A multirange paper-based analytical device for identifying low, moderate, and high P. aeruginosa bacterial loads in sputum samples.

Study of the probability of resistance to phage infection in a collection of clinical isolates of Pseudomonas aeruginosa in relation to the presence of Pf phages.

Addressing carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa: the potential of cefiderocol and ceftazidime/avibactam plus aztreonam therapy.

Pharmacodynamic interaction of apotransferrin and anti-pseudomonal antibiotics against extensively drug-resistant Pseudomonas aeruginosa in a dynamic PK/PD model.

Multiomics informed mathematical model for meropenem and tobramycin against hypermutable Pseudomonas aeruginosa.

Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel β-lactams in Pseudomonas aeruginosa.

Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing Pseudomonas aeruginosa infections: good enough to have another?

Emerging resistance mechanisms to newer β-lactams in Pseudomonas aeruginosa.